文献速递淋巴瘤

DUSP1 是毛细胞白血病疾病持续存在关键驱动因素及潜在治疗靶点

DUSP1 is a key driver of disease persistence and potential therapeutic target in hairy cell leukemia.
PubMed 文献 · Blood Adv · 2026-01-01

本研究对经克拉屈滨治疗的经典毛细胞白血病患者原代细胞行单细胞RNA测序,比较长期与短期缓解者及复发前后的细胞亚群。发现高表达DUSP1、FOS、JUND的亚群在所有患者中存在并在复发时持续或扩增,DUSP1抑制可逆转骨髓基质细胞对BRAF抑制剂诱导凋亡的保护。

要点

  • 高表达DUSP1的HCL亚群在所有患者中检出,复发时持续或扩增
  • 骨髓基质细胞共培养诱导DUSP1并保护HAIR-M细胞免受BRAF抑制剂凋亡
  • DUSP1抑制可克服基质细胞保护,为清除微小残留病提供依据

核心结论

  • DUSP1是HCL疾病持续存在的关键驱动因素,并可能是消除微小残留病、预防复发的潜在治疗靶点。

研究设计与样本

  • 对经克拉屈滨治疗的经典HCL患者分选原代HCL细胞行单细胞RNA测序,比较长期与短期缓解者诊断时及短期缓解者诊断与复发时样本。
  • 在缺乏合适BRAF V600E突变HCL细胞系的情况下,验证HAIR-M细胞(BRAF D594E)为HCL实验模型。

主要发现

  • 鉴定出DUSP1、FOS、JUND表达增高的HCL亚群,在所有患者中检出,复发时持续或扩增。
  • 癌症通路分析提示肿瘤微环境依赖性增强,表现为p38丝裂原活化蛋白激酶通路受抑制。
  • HAIR-M与骨髓基质细胞共培养强烈诱导DUSP1,并伴随对BRAF抑制剂诱导凋亡的保护。
  • DUSP1抑制可克服骨髓基质细胞诱导的凋亡保护。

关键数值与推荐

  • 短期缓解者定义为无进展生存期≤3年,长期缓解者为>10年。
  • 经典HCL以BRAF V600E驱动突变为特征,标准治疗为嘌呤类似物(如克拉屈滨),高达25%患者早期复发。
  • HAIR-M细胞携带BRAF D594E激活突变,可模拟V600E下游信号并被BRAF抑制剂有效靶向。

临床怎么用

  • 提示DUSP1抑制可能作为清除HCL微小残留病、预防复发的候选策略,尚待未来临床验证。

局限性

  • 研究缺乏合适的BRAF V600E突变HCL细胞系,实验验证采用BRAF D594E的HAIR-M模型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Classic hairy cell leukemia (HCL) is a rare indolent B-cell lymphoproliferative disorder characterized by the driver mutation BRAF V600E. Standard treatment with purine analogs (eg, cladribine) induces long-term remissions, but up to 25% of patients relapse early. Even when targeting BRAF V600E, residual HCL cells frequently persist in the bone marrow (BM). To identify additional biological alterations contributing to HCL persistence, we performed single-cell RNA sequencing of sorted primary HCL cells from long-term vs short-term cladribine responders (ST-R; >10 vs ≤3 years of progression-free survival) at diagnosis and from ST-R at diagnosis vs relapse. We identified a distinct HCL subcluster characterized by increased DUSP1, FOS, and JUND expression that was detected in all patients and persisted or even expanded at relapse. Cancer pathway analysis suggested enhanced tumor microenvironment dependence, as reflected by suppression of the p38 mitogen-activated protein kinase pathway. In the absence of a suitable BRAF V600E-mutated HCL cell line, we validated HAIR-M cells (BRAF D594E) as a bona fide experimental HCL model. The activating BRAF D594E mutation mimics V600E-induced downstream signaling that can be effectively targeted by BRAF inhibitors (BRAFi). HAIR-M coculture with BM stromal cells (BMSC) strongly induced DUSP1 and was accompanied by protection from BRAFi-induced HAIR-M apoptosis. The functional importance of DUSP1 was corroborated by showing that BMSC-induced protection from cell death could be overcome by DUSP1 inhibition. Our results may set the stage for future clinical testing of DUSP1 inhibition to eliminate minimal residual disease and prevent relapse in HCL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bohn JP, Scheiber A, Sturm G, et al. DUSP1 is a key driver of disease persistence and potential therapeutic target in hairy cell leukemia. Blood Adv. 2026. PMID: 42200459. doi:10.1182/bloodadvances.2025019057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。